Last update Feb. 21, 2018
Used in disorders of cognitive processes, such as dementia and learning difficulties, memory and attention (Fesenko 2009), in vertigo, in cortical myoclonus and in the prevention of sickle cell crisis.
Given the lack of scientific evidence of its efficacy (Al Hajeri 2016, Flicker 2001), it is considered to be a drug of little therapeutic use (SEFAF 2012, INSALUD 2001).
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic characteristics (low molecular weight, high oral bioavailability...) make its transfer into breast milk probable.
Side effects are rare and not serious (UCB 2013, AEMPS 2011).
It has been used in children in various studies (Di Ianni 1985, El-Hazmi 1996, Fesenko 2009). One study revealed several adverse effects (increased aggression, irritability and anxiety, among others) in children with Down syndrome who took Piracetam (Lobauhg 2001).
Given its proven lack of effectiveness and that it can transfer into breast milk, it is probably a non-essential medication during breastfeeding.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
If it is necessary to use it during breastfeeding, use the lowest effective dose and for the shortest possible period.
We do not have alternatives for πιρακετάμη.
Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.